ArticleScientific reports2025
Proteomics on choroidal neovascularization based on itraq and the protective effect of TAB1 in CNV.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Choroidal neovascularization (CNV) is a severe pathological outcome of age-related macular degeneration (AMD) which could lead to blindness. The present study was aimed at exploring the mechanisms of CNV, hoping to provide new clues in finding the treatment target of CNV. ITRAQ approach was applied to analyze the proteins in choroidal neovascularization of CNV and normal rats. KEGG and GO annotation were used to analyze the differently-expressed proteins. Western Blotting was used as the method to identify the differently-expressed proteins. TAB1, one of the differently-expressed proteins, was chosen as the study objective in the following research. AAV-TAB1 over-expression vehicle was constructed to investigate the function of TAB1 in CNV. IL-6 and IL-18 were tested with the use of ELISA. Western Blotting was used to test the expression of NF-kB pathway molecules. In terms of the results, expressions of 49 kinds of proteins were up-regulated in CNV rats while expressions of 241 kinds of proteins were down-regulated among the 4380 identified proteins. Overexpression of TAB1 significantly reduced areas of CNV lesions in vivo. Cell proliferation significantly increased in the TAB1 over-expressed group in RPE. IL-6 expression significantly increased in the TAB1-overexpression group while IL-18 expression significantly reduced. Western blotting results showed NF-kB pathway molecules were involved in it. The present study suggests TAB1 may play a protective role in CNV progression and the relative pathway owns the potential to be the treating target of CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.